Combination of targeted agents in metastatic renal cell carcinoma: A path forward or a dead-end street?

Cancer

Volumn 118, Issue 7, 2012, Pages 1744-1746

  Michaelson, M Dror ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ADVANCED CANCER; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; SKIN DISEASE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; PYRROLES; SIROLIMUS;

EID: 84858698436     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26427     Document Type: Editorial

References (21)

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
2. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. (Pubitemid 46849157)
3. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008;372: 449-456.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
5. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28:2137-2143.
6. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
7. Molina AM, Feldman DR, Voss MH, et al. Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;118:1868-1876.
8. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7:24-27.
9. Patnaik A, Ricart A, Cooper JS. A phase 1, pharmacokinetic and pharmacodynamic study of sorafenib, a multitargeted kinase inhibitor, in combination with temsirolimus, an mTOR inhibitor, in patients with advanced solid malignancies [abstract]. J Clin Oncol. 2007;25(18 suppl):Page. Abstract 3512.
10. Merchan JR, Liu G, Fitch T, et al. Phase 1 trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma [abstract]. J Clin Oncol. 2007;25(18 suppl):Page. Abstract 5034.
11. Harzstark AL, Small EJ, Weinberg VK, et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma [published online ahead of print March 8, 2011]. Cancer. doi: 10.1002/cncr.25931.
12. Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131-2136.
13. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27: 1432-1439.
14. Sosman JA, Flaherty K, Atkins MB, et al. Updated results of a phase 1 trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer [abstract]. J Clin Oncol. 2008;26:PAGE. Abstract 5011.
15. Semrad TJ, Eddings C, Dutia MP, Christensen S, Lau D, Lara P. Phase 1 study of temsirolimus and pazopanib in solid tumors with emphasis on renal cell carcinoma [abstract]. J Clin Oncol. 2011;29:PAGE. Abstract e15113.
16. Escudier B, Negrier S, Gravis G, et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal carcinoma? Results of the randomized TORAVA phase II trial. J Clin Oncol. 2010;28(15 suppl): 4516a.
17. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28:207-214.
18. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13:103-111.
19. Rini BI, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second- line therapy for metastatic renal cell carcinoma: results of phase 3 AXIS trial [abstract]. J Clin Oncol. 2011;29:Page. Abstract 4503.
20. Merchan JR, Pitot HC, Qin R. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients. J Clin Oncol. 2009;27:5039a.
21. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.